abstract |
The present invention is a combination of at least two components, component A and component B, wherein component A is the anti-CEACAM6 antibody TPP-3310 and component B is the anti-TIM-3 antibody, preferentially Cobolimab. Regarding combinations, which are MBG-453, BMS-986258, Sym-023, LY-321367 or INCAGN-2390. |